Dynavax Technologies | DVAX - Efectivo Y Equivalentes



Efectivo Y Equivalentes Cambio Fecha
AbbVie USD 5.23B 400M 2025-12
Adma Biologics USD 87.63M 26.24M 2025-12
Agenus USD 3.46M 6.08M 2025-09
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
Glaxosmithkline GBP 3.3B 303M 2025-09
Merck USD 18.17B 10.16B 2025-09
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
TG Therapeutics USD 199.51M 21.2M 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12